PhRMA and ClinicalTrials.gov
Executive Summary
Industry compliance with the ClinicalTrials.gov database was discussed at a July 15 board meeting of the Pharmaceutical Research & Manufacturers of America. "The heads of regulatory affairs at PhRMA member companies have said they believe they are in compliance" with ClinicalTrials.gov posting requirements. Data cited by Rep. Henry Waxman (D-Calif.) during a recent congressional hearing do not reflect the current rate of compliance, PhRMA said (1"The Pink Sheet" July 12, 2004, p. 4). The association believes a "fairer evaluation would look at what our companies submitted in 2003 and so far this year"...
You may also be interested in...
ClinicalTrials.gov Compliance Will Improve, PhRMA Tells Rep. Waxman
Industry may need several years to come into complete compliance with ClinicalTrials.gov, the Pharmaceutical Research & Manufacturers of America indicated in a letter to Rep. Henry Waxman (D-Calif.)
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.